Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceVideos

The European Commission grants final authorisation for isatuximab (Sarclisa®) for transplant eligible newly diagnosed myeloma patients

The European Commission (EC) has approved isatuximab (Sarclisa®) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction (i.e., initial) treatment of newly diagnosed myeloma patients (NDMM) who are eligible for autologous stem cell transplant.  The decision follows an earlier positive recommendation of the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP…

Read more

The European Commission grants final authorisation for belantamab mafodotin (Blenrep®) combinations for relapsed/refractory myeloma patients

Two belantamab mafodotin (Blenrep®) combinations, with bortezomib and dexamethasone or pomalidomide and dexamethasone, are now authorised for use in the European Union. The decision follows an earlier positive recommendation of European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP – their scientific advisory committee) on 23 May 2025. Marketing authorisation means that…

Read more

New guidelines for the treatment and the management of myeloma and smouldering myeloma

On July 7th, 2025, new clinical management guidelines for myeloma and smouldering myeloma were published in Nature Reviews Clinical Oncology by myeloma experts. These guidelines are written to guide doctors and healthcare professionals in myeloma and smouldering myeloma diagnosis, treatment and follow-up, based on the most up-to-date scientific knowledge. The last treatment guidelines were published in…

Read more

MPE member spotlight: Multiple Myeloma Ireland

On May 23rd, MPE member organisation, Multiple Myeloma Ireland (MMI) successfully hosted its 2025 Patient and Family Information Day at the Ashling Hotel in Dublin. Multiple Myeloma Ireland is the only charitable organisation in Ireland focused exclusively on supporting patients, families and carers with myeloma and related conditions. As a valued member of Myeloma Patients Europe (MPE), MMI…

Read more

EMA CHMP gives positive opinion on daratumumab use in smouldering myeloma patients with high risk of developing myeloma

On the 19th June 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended  marketing authorisation for daratumumab for patients with high-risk smouldering myeloma. Daratumumab is a monoclonal antibody marketed by Johnson & Johnson as Darzalex®. This medicine has been designed to recognise and bind to the CD38 protein, which is found on the surface…

Read more

EHA 2025 | Expert interviews

During the European Hematology Association (EHA) Annual Congress 2025, MPE conducted a series of expert interviews covering the most interesting updates in myeloma. These interviews focused on important research results and their potential to improve patient survival and quality of life. Dr. Sundar Jagannath discusses the long-term remission and survival for relapsed/refractory patients after treatment with ciltacabtagene…

Read more

Join our EHA 2025 highlights webinar

To help patients and advocates digest the most important myeloma news from the European Hematology Association (EHA) 2025 Annual Congress, the largest haematology event in Europe, Myeloma Patients Europe (MPE) will host a webinar on Tuesday, 24 June at 17:00 CET. The session will be led by Dr. Ulf-Henrik Mellqvist, Haematologist and Associate Professor at…

Read more
March

April 2026

May
MO
TU
WE
TH
FR
SA
SU
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
Events for 1st April
No Events
Events for 2nd April
No Events
Events for 3rd April
No Events
Events for 4th April
No Events
Events for 5th April
No Events
Events for 6th April
No Events
Events for 7th April
No Events
Events for 8th April
No Events
Events for 9th April
No Events
Events for 10th April
No Events
Events for 11th April
No Events
Events for 12th April
No Events
Events for 13th April
No Events
Events for 14th April
No Events
Events for 15th April
No Events
Events for 16th April
No Events
Events for 17th April
No Events
Events for 18th April
No Events
Events for 19th April
No Events
Events for 20th April
No Events
Events for 21st April
No Events
Events for 22nd April
No Events
Events for 23rd April
No Events
Events for 24th April
No Events
Events for 25th April
No Events
Events for 26th April
No Events
Events for 27th April
No Events
Events for 28th April
No Events
Events for 29th April
No Events
Events for 30th April
No Events